GIP and metabolic dysfunction-associated steatohepatitis: Other than T2DM, two clinical trials are ongoing to investigate the effect of NASH treatment (Effect on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue, NCT05751720, phase 1/2; A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) (SYNERGY-NASH), NCT04166773, phase 2).